You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Memo Therapeutics reveals positive AntiBKV data

Memo Therapeutics – a company which focuses on antibody discovery – has announced positive tolerability and safety data from its AntiBKV phase 1 clinical trial.